1,2,4-Trimethoxybenzene

1,2,4-Trimethoxybenzene (0.5-1 mM, 1.5 h) significantly inhibits Nigericin (HY-127019) and Lipopolysaccharides (HY-D1056) (LPS)-induced NLRP3 inflammasome activation in immortalized murine bone marrow-derived macrophages (iBMDMs), manifested as reduced caspase-1 (Casp-1) cleavage and IL-1β secretion^[1].
1,2,4-Trimethoxybenzene (1 mM, 75-90 min) inhibits LPS and ATP-induced NLRP3 activation in iBMDMs, primary microglia, and Primary macrophages cells^[1].
1,2,4-Trimethoxybenzene (75-90 min) inhibits nigericin-induced NLRP3 activation in iBMDMs and primary macrophages, while 1,2,3-TTB had no inhibitory effect, indicating that the inhibitory activity is structure-dependent^[1].
1,2,4-Trimethoxybenzene (45 min-2 h) does not inhibit LPS and poly(dA:dT)-induced activation of AIM2 inflammasome in primary peritoneal macrophages and iBMDMs^[1].
1,2,4-Trimethoxybenzene (1 h) reduces the formation of ASC specks in iBMDMs and Primary microglia induced by LPS and nigericin: immunofluorescence showed a significant reduction in the number of ASC specks; DSS crosslinking experiments showed an increase in soluble ASCs and a decrease in insoluble ASCs^[1].
1,2,4-Trimethoxybenzene (1 h) blocks the protein-protein interaction between NLRP3 and ASC in LPS-induced iBMDMs^[1].
1,2,4-Trimethoxybenzene (1 h) inhibits LPS and nigericin-induced NLRP3 oligomerization of iBMDMs and primary macrophages: DSS crosslinking experiments showed reduced formation of NLRP3 monomers, dimers and higher oligomers^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.